Full-Time

Territory Development Representative

Confirmed live in the last 24 hours

PROCEPT BioRobotics

PROCEPT BioRobotics

501-1,000 employees

Develops robotic solutions for BPH treatment

Compensation Overview

$85k/yr

+ Variable Compensation + Equity Compensation

Junior

Portland, OR, USA

Remote position targeting candidates based in Portland, OR.

Category
Inside Sales
Sales & Account Management
Required Skills
Sales
Lead Generation
Marketing
Requirements
  • Bachelor's degree in Business Administration, Marketing, Biomedical Engineering, or a related field
  • 1-2 years of experience in sales, preferably in the medical device or surgical sales industry
  • Strong technical aptitude and understanding of surgical procedures, robotics technology, and medical terminology
  • Ability to work independently and as part of a team, and to collaborate effectively with cross-functional teams
  • Ability to travel 80%
Responsibilities
  • Conduct thorough research to identify potential customers, including surgeons and hospitals
  • Utilize various channels (e.g., online research, industry events, cold calling, email campaigns) to generate new leads and expand the customer base
  • Conduct effective, in-person sales presentations and demonstrations to educate prospects and understand their needs, challenges, and buying potential
  • Cultivate relationships with key stakeholders, including surgeons, hospital administrators, and purchasing decision-makers
  • Nurture leads and maintain regular communication to ensure a positive customer experience and foster long-term partnerships
  • Collaborate closely with Robotic Sales Representatives to transfer qualified leads and provide accurate and comprehensive lead information
  • Provide ongoing support throughout the sales process, including assisting with market development events and logistics
  • Conduct product demonstrations for customers, including surgeons, nurses, operating room staff and hospital administrators, to showcase the value of Aquablation Therapy
  • Assist in closing deals and achieving sales targets by providing technical expertise, understanding customer needs, and developing customized solutions
Desired Qualifications
  • Experience in life sciences or healthcare industry or a regulated (FDA) environment a plus
  • Previous startup experience a plus, must have enthusiasm and ability to work in a fast paced environment
  • Excellent organizational and time management skills, including the ability to prioritize tasks and manage a busy sales schedule

PROCEPT BioRobotics develops robotic solutions specifically for treating benign prostatic hyperplasia (BPH), a condition that affects many older men by causing prostate enlargement and urinary issues. Their main product, the AquaBeam Robotic System, utilizes Aquablation therapy, which combines real-time imaging, robotics, and waterjet technology to precisely remove prostate tissue in a minimally invasive manner. This system is designed for urologists and healthcare facilities, focusing on improving patient outcomes and making surgical procedures more efficient. Unlike competitors, PROCEPT BioRobotics emphasizes predictable results and reduced complications, which has led to its recognition in clinical practice guidelines. The company's goal is to enhance the quality of life for patients suffering from BPH through advanced surgical technology.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2009

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval for Aquablation therapy in prostate cancer suggests expansion opportunities.
  • Significant investment in robotics highlights a robust funding environment for PROCEPT.
  • Long-term data confirms Aquablation therapy's efficacy, driving further clinical adoption.

What critics are saying

  • HYDROS™ Robotic System poses a competitive threat with advanced features.
  • Established companies like Intuitive Surgical challenge PROCEPT's market position.
  • Continuous R&D investment is needed to maintain technological leadership.

What makes PROCEPT BioRobotics unique

  • AquaBeam Robotic System offers minimally invasive BPH treatment with high precision.
  • Aquablation therapy provides effective outcomes regardless of prostate size or surgeon experience.
  • Over 100 peer-reviewed publications support the clinical advantages of Aquablation therapy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Company Match

401(k) Retirement Plan

Paid Vacation

Paid Parental Leave

Paid Holidays

Wellness Program

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

3%
Stock Titan
Mar 14th, 2025
PROCEPT BioRobotics(R) Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada

SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) - PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Venetian Hotel in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time.

Hit Consultant
Jan 27th, 2025
Mount Sinai Performs Nyc’S First Enlarged Prostate Procedure With Hydros™ Robotic System

What You Should Know:– The Mount Sinai Hospital has achieved a significant milestone in men’s health by performing New York City’s first procedures using the HYDROS™ Robotic System.– The technology offers a minimally invasive treatment option for benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate.Impact of BPHBPH is a prevalent condition affecting millions of men, particularly those over 60. While non-cancerous, BPH can significantly impact quality of life, causing urinary symptoms such as frequent urination, weak stream, and nighttime urgency.Minimally Invasive Procedure Offers Hope for Men with BPHThe HYDROS™ system represents a major advancement in BPH treatment, building upon traditional methods like transurethral resection of the prostate (TURP) and laser treatments. It offers several key innovations:AI-Powered Treatment Planning: The system utilizes FirstAssist AI™, an image recognition software that identifies critical anatomical structures using ultrasound, enabling personalized treatment plans tailored to each patient’s prostate anatomy.The system utilizes FirstAssist AI™, an image recognition software that identifies critical anatomical structures using ultrasound, enabling personalized treatment plans tailored to each patient’s prostate anatomy. Advanced Visualization: HYDROS™ combines advanced ultrasound imaging with digital cystoscopy, providing surgeons with a detailed, multi-dimensional view of the prostate for enhanced precision and surgical planning.HYDROS™ combines advanced ultrasound imaging with digital cystoscopy, providing surgeons with a detailed, multi-dimensional view of the prostate for enhanced precision and surgical planning. Robotic-Assisted Waterjet Resection: The system employs a robotic-assisted, heat-free waterjet to remove obstructive prostate tissue while preserving key anatomical structures, minimizing the risk of complications like incontinence or erectile dysfunction.The system employs a robotic-assisted, heat-free waterjet to remove obstructive prostate tissue while preserving key anatomical structures, minimizing the risk of complications like incontinence or erectile dysfunction. Streamlined Workflow: HYDROS™ features an integrated tower for efficient setup, an adjustable touchscreen for improved ergonomics, and user-friendly software to guide surgeons through the procedure.Early Success and Expanding AccessMount Sinai urologists have successfully performed the health system’s first three HYDROS™ procedures, with all patients responding well and being discharged the following day

The Robot Report
Jan 6th, 2025
Robotics Investments Top $7.4B In October 2024

Robotics investments topped $7.4 billion for the month of October 2024, the result of 77 funding rounds. The investment total was led by Waymo’s $5.6 billion raise, which is the largest single round of the year through November. October’s total was the largest through the first 10 months of the year. The previous monthly high was the $3.7 billion raised in September 2024. The total investment for the period of January through October 2024 was more than $20 billion. Developers of autonomous driving technologies once again dominated the list of largest investments for the month

Bizjournals
Oct 29th, 2024
Biotech firm announces $175M public stock offering

Procept BioRobotics announce a $175 million public stock offering, along with successful Q3 earnings.

MarketBeat
Aug 14th, 2024
Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?

PROCEPT BioRobotics operates in the medical sector and competes with medical robot and device makers like Intuitive Surgical, Medtronic PLC NYSE: MDT, and Zimmer Biomet Holdings NYSE: ZBH.